• Have fully understood the study and voluntarily signed the informed consent;

• Aged 18-75 years (including 18 and 75 years);

• Pathologically confirmed or potentially resectable locally advanced gastric/gastroesophageal junction adenocarcinoma (cT2-T4b, N+M0);

• If bone metastasis is suspected, a bone scan should be performed. If peritoneal metastasis is suspected, abdominal examination should be performed to rule out distant metastasis.

• At least 1 measurable lesion according to RECIST v1.1 criteria;

• United States Eastern Cancer Consortium (ECOG) Physical status score 0-1; BMI≥18;

• Expected survival ≥12 weeks;

• The functions of vital organs during the first 14 days of enrollment met the following requirements:

‣ Absolute neutrophil count ≥1.5×109/L;

⁃ Platelet ≥80×109/L;

⁃ Hemoglobin ≥90g/L;

⁃ Total bilirubin \< 1.5 ULN; ALT and AST \< 2.5 ULN (\< 5 ULN in patients with liver metastasis);

⁃ Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml/min;

⁃ endogenous creatinine clearance \> 50ml/min;

• Female subjects of childbearing age or male subjects whose sexual partner is a female of childbearing age should take effective contraceptive measures during the whole treatment period and 6 months after the treatment period;

⁃ Good compliance, cooperate with follow-up.